+91.9%
EMR vs MRNA
+156.2%
-64.4%
-29.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.8% | -4.8% | +6.6% | +2.0% |
| 7D | -2.7% | -20.9% | +18.2% | -1.8% |
| 30D | +1.3% | -13.3% | +14.5% | +1.7% |
| 3M | +3.0% | +212.6% | -209.5% | -4.1% |
| 6M | +23.4% | +309.0% | -285.7% | +9.5% |
| YTD | +23.9% | +567.3% | -543.4% | +2.3% |
| 1Y | +29.7% | +689.7% | -660.0% | +4.5% |
| All | +91.9% | +156.2% | -64.4% | +63.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling